Answers are grounded in this paper and cite their sources.
Results show that DR-TB had a substantial impact on patients' quality of life, but that AEs during the early months on treatment may be responsible for reducing HRQoL even further. Our findings highlight the negative effects of injectable agents on HRQoL. Patients require an integrative patient-centered approach to deal with DR-TB and HIV and the potential overlapping toxicities which may be worsened by concurrent treatment.
No takes yet. Share an insight, caveat, or question.
Sineke et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: